ALDH1A3 and cancer: Many non-specific covalent inhibitors of ALDH1A3 have been described, including the cytotoxic in vitro tool compound DEAB, as well as compounds that have been tested in humans, including the alcohol aversion compound disulfiram (Antabuse) that has been used clinically to inhibit ALDH2, the bisdiamine compound Win18446 that was tested in healthy volunteers, and dimethyl ampal thiolester (DIMATE), which is under development as a nanoencapsulated cancer therapeutic (ABD-3001) and is reported in phase 1 trials.6